☆ 4.4 Article

Dupilumab Treatment in Children Aged 6-11 Years With Atopic Dermatitis: A Multicentre, Real-Life Study

PEDIATRIC DRUGS (2022)

Related references

Note: Only part of the references are listed.

Letter Dermatology

Dupilumab in adolescents with moderate to severe atopic dermatitis: a 32-week real-world experience during the COVID-19 pandemic

K. Hansel et al.

CLINICAL AND EXPERIMENTAL DERMATOLOGY (2022)

Add to Collection

Article Dermatology

Effectiveness and safety of dupilumab in the treatment of atopic dermatitis in children (6-11 years): data from a French multicentre retrospective cohort in daily practice

A. Lasek et al.

Summary: This study evaluated the effectiveness and safety of Dupilumab in the daily practice of children aged 6-11 with moderate-to-severe atopic dermatitis (AD). The results showed a significant decrease in disease severity scores after 3 months of treatment, as well as a lower frequency of adverse events compared to previous trials. However, the administration of injectable form may present challenges in this age group. Overall, Dupilumab is an effective and safe treatment option for children with moderate-to-severe AD.

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2022)

Add to Collection

Article Dermatology

Dupilumab provides favourable long-term safety and efficacy in children aged ≥ 6 to < 12 years with uncontrolled severe atopic dermatitis: results from an open-label phase IIa study and subsequent phase III open-label extension study

M. J. Cork et al.

Summary: The study demonstrates that dupilumab improves symptoms in children aged 6 to 12 with severe atopic dermatitis, showing acceptable safety and long-term efficacy. The drug concentration and safety were well validated in the study.

BRITISH JOURNAL OF DERMATOLOGY (2021)

Add to Collection

Article Allergy

Atopic dermatitis in the pediatric population A cross-sectional, international epidemiologic study

Jonathan Silverberg et al.

Summary: This global survey in 18 countries revealed that atopic dermatitis affects a substantial proportion of the pediatric population, with less than 15% having severe cases. Prevalence and severity varied across countries and age groups, with rural areas generally having lower prevalence than urban or suburban areas.

ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY (2021)

Add to Collection

Article Dermatology

Dupilumab therapy of atopic dermatitis of the elderly: a multicentre, real-life study

C. Patruno et al.

Summary: This study retrospectively observed the efficacy and safety of dupilumab in treating severe atopic dermatitis in patients aged 65 and above. The results indicated that there were no significant differences in efficacy and safety of dupilumab between elderly patients and those aged 18-64, showing good efficacy and safety in treating atopic dermatitis.

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2021)

Add to Collection

Article Dermatology

Efficacy and Safety of Dupilumab in Clinical Practice: One Year of Experience on 165 Adult Patients from a Tertiary Referral Centre

Maddalena Napolitano et al.

Summary: This study confirms the long-term effectiveness and favorable safety profile of dupilumab in treating moderate-to-severe adult atopic dermatitis, showing significant improvement in disease severity scores and low discontinuation rates due to adverse events.

DERMATOLOGY AND THERAPY (2021)

Add to Collection

Article Dermatology

Effectiveness and Safety of Long-Term Dupilumab Treatment in Elderly Patients with Atopic Dermatitis: A Multicenter Real-Life Observational Study

Cataldo Patruno et al.

Summary: The study evaluated the efficacy and safety of Dupilumab in treating elderly patients with atopic dermatitis over 52 weeks. Results showed a reduction in disease severity scores and a low rate of adverse events, indicating that Dupilumab is an effective and safe long-term treatment option for atopic dermatitis in patients aged over 65 years.

AMERICAN JOURNAL OF CLINICAL DERMATOLOGY (2021)

Add to Collection

Article Dermatology

Atopic dermatitis in adolescents: Effectiveness and safety of dupilumab in a 16-week real-life experience during the COVID-19 pandemic in Italy

Luca Stingeni et al.

Summary: This study reported the real-world effectiveness and safety of dupilumab in adolescents with moderate to severe AD during the COVID-19 pandemic in Italy from January to October 2020. The results showed excellent effectiveness of dupilumab with higher improvement than observed in clinical trials, and a good safety profile was maintained throughout the treatment period, despite one patient contracting asymptomatic SARS-CoV-2 infection and another developing mild conjunctivitis.

DERMATOLOGIC THERAPY (2021)

Add to Collection

Review Medicine, General & Internal

Safety of topical corticosteroids in atopic eczema: an umbrella review

Emma Axon et al.

Summary: An umbrella review of 38 systematic reviews found that the safety of topical corticosteroids in treating atopic eczema is generally high, especially when used intermittently to treat flares or prevent them. No significant harmful effects were identified, but data on long-term safety remains limited.

BMJ OPEN (2021)

Add to Collection

Review Dermatology

Off-label use of dupilumab for pediatric patients with atopic dermatitis: A multicenter retrospective review

Sean Igelman et al.

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2020)

Add to Collection

Article Pediatrics

Infant sleep and child mental health: a longitudinal investigation

Fallon Cook et al.

ARCHIVES OF DISEASE IN CHILDHOOD (2020)

Add to Collection

Article Dermatology

Efficacy and safety of dupilumab with concomitant topical corticosteroids in children 6 to 11 years old with severe atopic dermatitis: A randomized, double-blinded, placebo-controlled phase 3 trial

Amy S. Paller et al.

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2020)

Add to Collection

Review Dermatology

Counting the Burden: Atopic Dermatitis and Health-related Quality of Life

Faraz Ali et al.

ACTA DERMATO-VENEREOLOGICA (2020)

Add to Collection

Article Dermatology

The blood proteomic signature of early-onset pediatric atopic dermatitis shows systemic inflammation and is distinct from adult long-standing disease

Patrick M. Brunner et al.

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2019)

Add to Collection

Article Behavioral Sciences

Sleep Difficulties in Infancy Are Associated with Symptoms of Inattention and Hyperactivity at the Age of 5 Years: A Longitudinal Study

Hanna Huhdanpaa et al.

JOURNAL OF DEVELOPMENTAL AND BEHAVIORAL PEDIATRICS (2019)

Add to Collection

Article Dermatology

Use of systemic corticosteroids for atopic dermatitis: International Eczema Council consensus statement

A. M. Drucker et al.

BRITISH JOURNAL OF DERMATOLOGY (2018)

Add to Collection

Article Dermatology

Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo-controlled, randomized phase III clinical trial (LIBERTY AD CAFE)

M. de Bruin-Weller et al.

BRITISH JOURNAL OF DERMATOLOGY (2018)

Add to Collection

Article Dermatology

Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: partII

A. Wollenberg et al.

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2018)

Add to Collection

Article Dermatology

Prescribing practices for systemic agents in the treatment of severe pediatric atopic dermatitis in the US and Canada: The PeDRA TREAT survey

Christine R. Totri et al.

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2017)

Add to Collection

Article Medicine, General & Internal

Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial

Andrew Blauvelt et al.

LANCET (2017)

Add to Collection

Article Allergy

Early-onset pediatric atopic dermatitis is TH2 but also TH17 polarized in skin

Hitokazu Esaki et al.

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2016)

Add to Collection

Review Dermatology

Psychodermatologic Effects of Atopic Dermatitis and Acne: A Review on Self-Esteem and Identity

Catherine M. Nguyen et al.

PEDIATRIC DERMATOLOGY (2016)

Add to Collection

Article Allergy

Atopic dermatitis from adolescence to adulthood in the TOACS cohort: prevalence, persistence and comorbidities

C. G. Mortz et al.

ALLERGY (2015)

Add to Collection

Article Dermatology

Guidelines of care for the management of atopic dermatitis Section 2. Management and treatment of atopic dermatitis with topical therapies

Lawrence F. Eichenfield et al.

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2014)

Add to Collection

Article Allergy

Systemic therapies for severe atopic dermatitis in children and adults

Carsten Flohr et al.

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2013)

Add to Collection

© Peeref 2019-2024. All rights reserved.